Cytogenetic Risk
세포유전학적 위험

Cytogenetic Risk(세포유전학적 위험)란 무엇입니까?

Cytogenetic Risk 세포유전학적 위험 - Mutation patterns and OS differed between the 84 patients with poor-risk cytogenetics and the 387 patients with good (N=13), intermediate (N=339) or unavailable (N=35) cytogenetic risk. ^[1] Analysis of the kinetics of cells reaching first or second (and higher) mitosis after irradiation and aberration data obtained by the multiplex fluorescence in situ hybridization (mFISH) technique are used to determine of the cytogenetic risk, i. ^[2] After a multi-step selection process, characteristics with the greatest importance for the therapy prognosis were selected: age at the beginning of therapy, line of therapy, time after MM verification, ECOG (Eastern Cooperative Oncology Group), cytogenetic risk, transplant eligibible or not, TTNT after the previous line of therapy, therapy regimen. ^[3] Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. ^[4] Based on AML cases with intermediate and adverse-cytogenetic risk in the Cancer Genome Atlas (TCGA) database, 64 immune-related differentially expressed genes (DEGs) among patients with RUNX1, TP53, or ASXL1 mutations and patients without these mutations were identified. ^[5] These socioeconomic factors, in addition to marital status, were then assessed individually and as a cumulative socioeconomic score for prognostic significance in a cohort of 2543 patients treated at a tertiary care center utilizing known biologic risk factors, such as cytogenetic risk, International Staging System classification, and serum lactate dehydrogenase levels. ^[6] These results were independent of the cytogenetic risk of conditioning intensity. ^[7] Our work has identified a gene signature associated with the histone demethylase KDM4A, the KDM4A-9 score, which is associated with poor OS and independent of age, cytogenetic risk and mutation status (2). ^[8] The common significant prognostic factors among patients undergoing allo‐HCT were age, performance status, percentage of peripheral blasts, cytogenetic risk, chemotherapy response, and number of transplantations. ^[9] Isatuximab–pomalidomide–dexamethasone provides a consistent benefit over pomalidomide–dexamethasone treatment in RRMM patients regardless of cytogenetic risk. ^[10] Cytogenetic risk was low in 16. ^[11] Mutation patterns and OS differed between the 84 patients with poor-risk cytogenetics and the 387 patients with good (n = 13), intermediate (n = 339), or unmeasured (n = 35) cytogenetic risk. ^[12] R-ISS classification and cytogenetic risk were available for 968 and 970 patients respectively. ^[13] Pts will be stratified by cytogenetic risk (high vs standard/unknown) and randomized 1:1 to 28-day cycles of lenalidomide maintenance (10 mg PO;D1-28 [dose increasing to 15 mg if tolerated]) ± DARA SC (DARA 1,800 mg co-formulated with recombinant human hyaluronidase PH20 [rHuPH20;2,000 U/mL;ENHANZE®drug delivery technology, Halozyme, Inc. ^[14] These data suggest that selinexor can confer benefits to patients with MM regardless of cytogenetic risk. ^[15] The only factor influencing overall and progression-free survival was cytogenetic risk at transplantation. ^[16] 011), and poor and very poor revised International Prognostic Scoring System (IPSS-R) cytogenetic risk (HR, 4. ^[17] PBO on OS and RFS, adjusting for BL age, sex, ECOG PS score, cytogenetic risk at diagnosis (Dx), prior MDS, geographic region, CR/CRi after induction (per investigator) and at BL (per sponsor), MRD status, receipt of consolidation, number of consolidation cycles, platelet count, and ANC. ^[18] These models were adjusted for the following clinically relevant variables, as they were potential confounders of the examined associations: other treatment classes received, age, sex, race, practice type, year of therapy line, and cytogenetic risk. ^[19] Other characteristics, including cytogenetic risk were similar. ^[20] However, when stratified by cytogenetic risk, the median TTNT and OS were 16 and 51 months for standard risk vs 9 and 19 months for high risk (P=. ^[21] Adjusting for age, ISS stage 3, cytogenetic risk, Rd maintenance, and lenalidomide refractoriness at salvage, daratumumab-based therapy was associated with a significantly improved PFS [hazard ratio 0. ^[22] 01 after adjustment for age, cytogenetic risk, transplant year, donor, conditioning intensity, sex matching, interval diagnosis-relapse and relapse-allogeneic HCT as compared to chemotherapy consolidation. ^[23] Data on demographics, AML status, cytogenetic risks per European Leukemia Network (ELN), response, age, comorbidities per the HCT-comorbidity index (CI), function, frailty, geriatric assessment, cognition, Karnofsky performance status (KPS), QOL, social support, and depression were collected at enrollment and at 1, 3, 6, 9, 12, 18, and 24 months thereafter. ^[24] Efficacy results for these regimens have generally been consistent across subgroups defined by age, transplant eligibility, and cytogenetic risk. ^[25] Cytogenetic risk (CyR) were classified into high [-17p, t(4;14), t(14;16), 1q gain, t(14;20)] and standard risk [all others including trisomies, t(11;14), t(6;14)], based on the updated mSMART criteria. ^[26] Further trials confirmed that lenalidomide maintenance increases rates of high-quality responses and one study demonstrated that lenalidomide maintenance improves outcomes regardless of cytogenetic risk. ^[27] We divided them into three groups based on their cytogenetic risks: standard risk (SR), high risk (HR), and unknown risk. ^[28] Cox regression analysis (stage, cytogenetic risk, ASCT) confirmed that MRD is an independent prognostic factor of PFS and OS.